Beyond weight loss: what a Lancet review says about GLP-1 medications

• A 2026 Lancet Diabetes & Endocrinology review (PubMed 42208956) examined GLP-1 evidence across cardiovascular disease, kidney disease, sleep apnea, PCOS, osteoarthritis, muscle loss, depression, and cancer risk
• The authors conclude: 'overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions'
• Some of these benefits may be weight-independent — meaning they don't require weight loss to occur
• GLP-1s are FDA-approved for type 2 diabetes and chronic weight management only — the other conditions discussed in the review are not approved indications
• The evidence base varies significantly by condition: strong for cardiovascular disease, preliminary or observational for several others

The review — 'Beyond weight loss: multisystem benefits of obesity medications,' published in Lancet Diabetes & Endocrinology (PIIS2213-8587(26)00100-2, PubMed 42208956) — examined existing trial data, meta-analyses, and observational studies across eight condition areas:

1. Cardiovascular disease — including heart failure, atherosclerosis, and major adverse cardiac events
2. Kidney disease — including proteinuria reduction and progression of chronic kidney disease
3. Sleep apnea — including severity reduction in obstructive sleep apnea
4. Polycystic ovary syndrome (PCOS) — including improvements in metabolic and hormonal markers
5. Osteoarthritis — including joint pain and functional outcomes
6. Muscle loss (sarcopenia) — including lean mass changes during weight loss
7. Depression and mental health — including observational signals on mood and depression risk
8. Cancer risk — including observational data linking GLP-1 use to lower risk of certain cancers

The review's overarching conclusion is that GLP-1-based therapies show beneficial effects across these conditions — but with important caveats about evidence quality and mechanism.

The strongest evidence in the review is for cardiovascular outcomes, which has the backing of large randomized controlled trials:

• The SELECT trial (NEJM, 2023–2024) showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes
• Tirzepatide has shown cardiovascular risk reduction signals in the SURMOUNT-MMO trial data
• Cardiovascular benefit from GLP-1s in people with type 2 diabetes is well-established from earlier trials (LEADER, SUSTAIN-6, PIONEER-6)

Kidney disease evidence has also strengthened. The FLOW trial showed semaglutide reduced the risk of major kidney disease events in people with type 2 diabetes and chronic kidney disease. This was significant enough that semaglutide received an FDA indication for reducing risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease.

For sleep apnea, a Phase 3 trial (SURMOUNT-OSA) showed that tirzepatide significantly reduced apnea-hypopnea index (AHI) scores in adults with obesity and moderate-to-severe obstructive sleep apnea — enough for FDA to approve tirzepatide for treatment of moderate-to-severe OSA in adults with obesity alongside Zepbound's existing indication.

For PCOS, osteoarthritis, depression, and cancer risk, the evidence base is less mature:

• PCOS data is largely from small trials and observational studies showing improvements in insulin resistance, hormonal markers, and menstrual regularity. No large RCT has been completed specifically for GLP-1s in PCOS.
• Osteoarthritis data is mostly from trials that measured joint pain as a secondary outcome in weight-loss studies — not dedicated OA trials. GLP-1s are not FDA-approved for OA.
• Depression and mental health data is largely observational. Some studies have found associations between GLP-1 use and lower depression risk or improved mood, but causation is not established. These signals also carry a complexity: GLP-1s can occasionally cause depression or suicidal ideation as adverse events in some patients, and the FDA's prescribing information for semaglutide notes this.
• Cancer risk data is observational and early. Some retrospective studies have found lower incidence of certain cancers (colorectal, liver) in GLP-1 users, but no prospective RCT has tested cancer prevention as a primary outcome.

One of the review's more significant contributions is examining whether GLP-1 benefits are mediated through weight loss or through direct drug action on other tissues.

The authors note that 'some may be weight-independent' — meaning the drug may be doing something at the tissue or cellular level that wouldn't occur simply from losing weight by other means.

This is biologically plausible: GLP-1 receptors are found in the heart, kidneys, brain, and immune cells — not just in the gut and pancreas. Some cardiovascular benefits in trials appear larger than would be expected from weight loss alone. But separating weight-mediated from weight-independent effects requires study designs that are difficult to execute, and the question is not yet fully resolved for most conditions.

The phrase 'disease-modifying' carries a specific meaning in medicine: a therapy that alters the underlying course of a disease, rather than simply managing symptoms. It's a clinical framing, not a regulatory status.

GLP-1s are not FDA-approved as disease-modifying therapies for the conditions discussed in this review (with limited exceptions noted above). Using this language in a clinical setting means the treating clinician believes the evidence supports a meaningful impact on disease progression — not that FDA has reviewed or endorsed that interpretation.

What the Lancet review signals is that the clinical framing of GLP-1s is evolving. They were once viewed narrowly as diabetes drugs. Then as weight-loss drugs. The evidence now supports a more complex picture — one that warrants discussion with a clinician who can assess your individual risk profile across multiple conditions.

• Whether long-term use of GLP-1s produces sustained multisystem benefits beyond the trial periods studied (most trials ran 1–3 years)
• How weight-independent vs. weight-mediated effects break down for each condition
• Whether benefits persist after discontinuation of GLP-1 therapy, or return toward baseline
• The evidence base for newer dual and triple agonists (tirzepatide, retatrutide) is less mature than for older GLP-1 RAs like semaglutide

• Based on my full health profile, are there conditions beyond weight management that might benefit from GLP-1 therapy?
• Does my cardiovascular or kidney disease risk factor into the choice between different GLP-1 medications?
• Are there conditions I have where GLP-1 evidence is weaker — where I should temper my expectations?
• What other interventions (diet, exercise, other medications) work alongside GLP-1s for my specific conditions?

• Cardiovascular risk markers (blood pressure, LDL, triglycerides, CRP if ordered)
• Kidney function (eGFR, urine albumin-to-creatinine ratio if applicable)
• Sleep quality and any improvements in OSA symptoms if applicable
• Mental health — and report any changes in mood, depression, or unusual thoughts to your prescriber

Calling GLP-1s 'disease-modifying' isn't hype if the underlying evidence is examined carefully. The cardiovascular and kidney data is strong enough that the FDA has recognized it through approvals. For other conditions, the signals are real but the evidence base remains early. That distinction is worth holding onto — and discussing with the clinician who knows your case.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Lancet Diabetes & Endocrinology review — thelancet.com/journals/landia/article/PIIS2213-8587(26)00100-2/abstract
• PubMed 42208956 — pubmed.ncbi.nlm.nih.gov/42208956
• SELECT trial (NEJM) — for cardiovascular evidence context
• FLOW trial for kidney disease evidence (semaglutide CKD indication)
• FDA Zepbound prescribing information (OSA indication)